Knowledge Transfer Network
Cyclofluidic Ltd, based in biopark, Cambridge, have been developing rapid screening using flow chemistry developed in the labs of Prof Steve Ley at Cambridge University. The project began at Manchester University and with a lot of hard work and the help of Innovate UK funding and private investors has continued to grow.
CyclOps™ connects flow chemistry, purification, screening and drug design with complex algorithms allowing drug lead molecules to be assayed minutes, rather than weeks, after they are designed. Their unique approach puts synthesis, screening and molecular design firmly back together in a single laboratory allowing fast iterative exploration of vast areas of diverse chemical space. Further information on Cyclofluidic’s technology can be found here.
Cyclofluidic are committed to investing in the CylOps™ research platform to provide learning and improvement for all current and future partners and believe the newly evolving R&D ecosystem is a great place to do innovative science and support our partners large and small. Cyclofluidic now wish to develop the next generation of their novel automated molecular discovery technology by translating this technology to other sectors and are currently seeking partners, with an interest in working with them. The demand for consistent on specification nanoparticles for the printed electronics and health sectors may offer the ideal starting point.
For more information or to discuss partnering opportunities please contact KTN’s Rachael Rowlands-Jones.
Get updates on the latest chemistry news, events, funding opportunities and more.